Commentary · 8 Oct 2025
Conference abstractPublished 2019
Personalized and Regeneration Medicine require a Coagulum- OMICs Model
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: In 2017, a program on patient blood management was posted to the National External Quality Assurance Scheme conference for hemostasis and thrombosis [1]. This subsequent coagulum-OMIC framework is a standard for predictive value within personalized and regeneration medicine. An OMIC model is a foresight by the author of this program to achieve OMIC flow [View Fig. 1.]. This model sustains the success of Coagulum-OMICS when supported with the ISO 9000 series. [2] [3] [4]. Study: ISO 9001 and 9004 are powerful tools to identify and define good practice in an OMIC model. ISO 9001 is a process based standard and an ideal standard for OMIC interfaces. The greater challenge in haemostasis and thrombosis is the end to end process involves several parts of healthcare under different clinical management or vendor arrangements. The flexibility of ISO 9004 makes it an ideal tool to access Coagulum-OMICs and sustain the success of personalised and regeneration medicine. Program Development: A strategy for Research, Family, Organ and Acute Coagulum-OMICs commences biphasic policy objectives for genomics as a primary care with viscoelastic science, coagulum and platelet proteomics [Fig. 2]. Model OMIC development, resources, performance review and innovation, become learned. OMIC teams self-assess the Coagulum-OMICs to identify conformity with the model. Regional committees are supported by a joint working group on quality assurance to manage or improve OMICs Conclusion: A model for blood coagulum-OMICs is a benchmark to sustain excellence in the future of biological systems. The agility of Coagulum- OMICS to transverse primary and secondary care with genomic [pharma] pre-exams and viscoelastic or proteomic exams makes it a perfect learning initiative, self-assessment tool and governance program. The caveat is a need for expertise to sustain the success of coagulum-OMICs, in situ, with personalised and regeneration medicine.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Annals of Clinical and Laboratory Research.
Mini review · 2 Oct 2025
Characteristics and Treatment of Juvenile Myasthenia Gravis
Commentary · 9 Jul 2025
Commentary on Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: Real-World Data from 134 Patients
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAnnals of Clinical and Laboratory Research
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “James Henry”

